---
title: "Beijing's 'North Brain One' Implant Enters a 36-Patient Trial"
date: 2026-11-22
category: Brain–Computer Interface
site: NeuroAI
canonical: https://neuroai.site/a/na-brain-north-brain-one-gcp-trial
language: en
---

# Beijing's 'North Brain One' Implant Enters a 36-Patient Trial

> A 128-channel semi-invasive system moves from exploratory implants into a registered multicentre study — the slow road to a medical device.

On a morning in late March, two surgical teams in Beijing worked on separate patients at separate hospitals. The operations were almost routine in their precision: a small opening, a thin strip of electrodes laid over the brain's outer membrane, a wireless implant fixed in place. What made the day different was that the operations belonged to a registered clinical trial rather than an exploratory study.

The system is called North Brain One (北脑一号), developed by the Chinese Institute for Brain Research (北京脑科学与类脑研究所) in Beijing together with Beijing XinzhiDa Neurotechnology (北京芯智达神经技术有限公司). It is semi-invasive: the electrodes sit above the dura mater, so they never enter brain tissue. That design choice trades some signal quality for a lower risk profile, and it is now being tested at a scale that earlier Chinese brain-computer interface (脑机接口) projects did not attempt.

## Key takeaways

- North Brain One uses 128 flexible electrodes placed on the outer surface of the brain, with wireless power and data transmission.

- In March 2026, the first two patients were implanted under a GCP multicentre registered trial at Tiantan and Xuanwu hospitals.

- The trial plans to enrol 36 patients with spinal cord injury.

- Before the trial, the system had been used in seven exploratory cases with more than 45,000 cumulative hours of safe operation.

- A separate, fully invasive system, North Brain Two (北脑二号), has a 512-channel wireless version in development.

## Why 128 channels, and why on the surface

In brain-computer interfaces, channel count is a rough proxy for how much neural activity can be read at once. More channels mean a finer picture of intention. But reaching those channels normally means penetrating brain tissue, which provokes an immune response and complicates long-term use.

North Brain One's answer is density without penetration. Its 128 flexible electrodes are arranged on a strip laid over the dura. The institute describes this as a high-throughput semi-invasive approach, with miniaturised integration, wireless communication, and real-time encoding and decoding built into the system. The result is a middle path: cleaner signals than a scalp cap, without the tissue damage of penetrating arrays.

The wireless design removes the through-skin connector, a common source of infection and mechanical failure in implanted devices. For a system meant to be used at home for rehabilitation, that matters.

## From exploratory use to registered evidence

The distinction between an exploratory implant and a registered trial is easy to miss and important to understand. In exploratory work, researchers choose patients and protocols themselves. In a registered trial following good clinical practice (GCP), the protocol, endpoints, and follow-up are fixed in advance, and the data is expected to support a regulatory submission.

According to the institute, seven patients had received the system in the year before the trial, with cumulative safe operation exceeding 45,000 hours. On 31 March 2026, teams at Tiantan Hospital and Xuanwu Hospital implanted the first two patients in the multicentre study. The plan is to enrol 36 participants and follow them long enough to evaluate safety and effectiveness in rebuilding movement function after spinal cord injury.

The system had been presented as a major achievement at the 2026 Zhongguancun Forum in March; by June, state media reported that nearly 30 patients had received the implant and that cumulative safe operating time had passed 70,000 hours.

The developer's stated timetable is to complete enrolment in 2026 and apply for a Class III medical device registration certificate in 2027. Class III is the category for implantable devices, which carries the strongest review requirements.

## The second system

The institute is also pursuing the harder route. North Brain Two uses flexible microfilament electrodes placed directly in brain tissue, allowing recording from individual neurons. A wired version has been shown in animal studies; a wireless 512-channel version has been developed and was expected to enter clinical validation in 2026, according to People's Daily.

Holding both routes in one organisation is unusual. Most teams commit to one philosophy. Here, the semi-invasive system can generate near-term clinical evidence and revenue, while the invasive system explores higher-bandwidth applications such as fine motor control and perhaps cognitive functions. Whether the second system ever reaches patients depends on questions the first system cannot answer.

## Honest limitations

- The 128-channel and 512-channel figures, the 45,000 and 70,000 operating-hour totals, and the 36-patient target all come from the institute and Chinese state media. I found no independent verification.

- "Safe operation" is a system uptime measure, not a clinical outcome. It says nothing about whether patients improved.

- The trial was ongoing at the time of reporting. No completed results have been published.

- A registration certificate is not guaranteed by enrolment; the 2027 date is the developer's plan, not an approval.

- I have kept this article to the systems and institutions involved and avoided broader claims about national policy or international standing, which are not supported by the technical evidence alone.

## What readers can do now

- When you see an implant described as "wireless," check whether it means wireless data only, or both power and data. The second is harder and more useful.

- Follow registered trial identifiers and publication dates. A trial that reports patient numbers without endpoints is still a work in progress.

- If you are affected by spinal cord injury, ask a rehabilitation physician which trials are recruiting and what the inclusion criteria are. Enthusiasm is not eligibility.

---

Published by NeuroAI (https://neuroai.site/) — https://neuroai.site/a/na-brain-north-brain-one-gcp-trial
Free to quote with attribution and a link to the original.
